Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial Life Science Investing
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma Life Science Investing
U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma Pharmaceutical Investing
Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases Pharmaceutical Investing
Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology Pharmaceutical Investing
Albert Labs signs Letter of Intent with iNGEN? CRO for First In-Human Clinical Studies Pharmaceutical Investing
Canadian Migraine Sufferers Have New Treatment Option - Health Canada Approves UBRELVY® Pharmaceutical Investing
BriaCell CEO Discusses Positive Clinical Results of its Breast Cancer Immunotherapy Treatment in an Audio Interview with SmallCapVoice.com Pharmaceutical Investing
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Pharmaceutical Investing
